This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
While current treatment and liver transplantation strategies are reasonably effective for patients with early stage liver cancer, once the disease has advanced it becomes much harder to treat. Checkpoint immunotherapy has provided relief for some patients with advanced liver cancer, but the majority of patients still either don’t respond to the treatment or else develop resistance after initially responding. To address this, Dr. Guangchuan Wang is using a novel gene-editing approach to discover new factors that are responsible for resistance to immunotherapy. Identifying and validating the contribution of these factors will provide insights that could be used to improve immunotherapy approaches for liver cancer by helping doctors determine treatments might work best for which patients as well as highlighting novel targets for which future therapies could be developed.
Yale University | Liver Cancer | 2017 | Sidi Chen, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
This Skin Cancer Awareness month, discover new research, treatments, and progress for a future immune to skin cancer.
Birdies & Brews mixes beer and golf while raising funds for cancer immunotherapy research.